Cure My Disease

Don't miss your cure!

 Log in / Sign up

A camera that sees invisible light could guide kidney tumor removal

NCT ID NCT07803315

Knowledge-focused Sponsor: University of Leipzig Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are testing whether hyperspectral imaging, a camera technique that captures hundreds of light bands invisible to the eye, can map blood flow and identify tumor types during robot-assisted partial nephrectomy. The study will enroll 60 adults with kidney tumors up to 7 cm who are already scheduled for surgery. The imaging happens during the operation, with no extra tests for participants. The goal is to see if this technique can help surgeons distinguish healthy tissue from tumor and understand how clamping affects kidney blood flow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperspectral imaging
What this could lead to
If it works, this imaging technique could help surgeons see blood flow and tumor type in real time during kidney surgery, potentially improving precision and outcomes.
What could go wrong
This is an observational study with 60 participants, so it will not prove the technique changes outcomes. The imaging may not reliably distinguish tumor types or predict kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants for the trial will be selected from all patients referred to the Department of Urology at the University Hospital Leipzig for undergoing partial nephrectomy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a kidney tumor ≤7cm * planned robot-assisted partial nephrectomy * age ≥ 18 years Exclusion Criteria: * patients with a previous surgery on the affected kidney * patients with a fully intrarenal/endophytic tumor without an exophytic component * previous malignancy with ongoing or planned nephrotoxic chemotherapy * current immunosuppression (e.g., organ transplantation, leukemia) * pregnancy, lactation, or women who wish to have children * inability to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney neoplasm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer kidney neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney neoplasm Renal mass up to 7CM

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Leipzig

    RECRUITING

    Leipzig, 04103, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.